Prosecution Insights
Last updated: April 17, 2026
Application No. 17/021,784

Compressing, storing and searching sequence data

Final Rejection §DP
Filed
Sep 15, 2020
Examiner
ZEMAN, MARY K
Art Unit
1686
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
unknown
OA Round
4 (Final)
59%
Grant Probability
Moderate
5-6
OA Rounds
4y 1m
To Grant
93%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allow Rate
315 granted / 532 resolved
-0.8% vs TC avg
Strong +34% interview lift
Without
With
+33.9%
Interview Lift
resolved cases with interview
Typical timeline
4y 1m
Avg Prosecution
28 currently pending
Career history
560
Total Applications
across all art units

Statute-Specific Performance

§101
33.7%
-6.3% vs TC avg
§103
12.4%
-27.6% vs TC avg
§102
18.8%
-21.2% vs TC avg
§112
23.4%
-16.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 532 resolved cases

Office Action

§DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. Claims 1, 4-9 are under examination. Applicant’s arguments, filed 12/4/2025, noted that a terminal disclaimer would be forthcoming, however, no TD is of record as of the date of the writing of this action. As this is the remaining rejection, filing the TD is appropriate. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1, 4-9 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-16 of U.S. Patent No. 9715574. Although the claims at issue are not identical, they are not patentably distinct from each other because the claims of the application are generic to the claims of the patent, encompassing the same two-part data structure of nucleotide or genomic sequence data, wherein certain fragments of the sequence data have been replaced by links or pointers, then in response to a query, matching portions of the original sequence data are recovered and searched. The same coarse- to- fine grain thresholds are applied, and can be carried out using known search algorithms such as BLAST/ BLAT. The instant application is generic to the parent patent. The original parent separated methods, from a combined computer program product/ system group. The ‘574 is directed to systems, and the computer program products were not patented. Thus, this rejection is appropriate. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARY K ZEMAN whose telephone number is 5712720723. The examiner can normally be reached on 8am-2pm M-F. Email may be sent to mary.zeman@uspto.gov if the appropriate permissions have been filed. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Larry Riggs can be reached on 571 270-3062. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MARY K ZEMAN/ Primary Examiner, Art Unit 1686
Read full office action

Prosecution Timeline

Sep 15, 2020
Application Filed
Jan 30, 2024
Non-Final Rejection — §DP
Aug 02, 2024
Response Filed
Oct 11, 2024
Final Rejection — §DP
Apr 17, 2025
Request for Continued Examination
Apr 21, 2025
Response after Non-Final Action
Jun 02, 2025
Non-Final Rejection — §DP
Dec 04, 2025
Response Filed
Jan 22, 2026
Final Rejection — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12586663
COPY NUMBER VARIANT CALLER
2y 5m to grant Granted Mar 24, 2026
Patent 12580051
IDENTIFYING METHYLATION PATTERNS THAT DISCRIMINATE OR INDICATE A CANCER CONDITION
2y 5m to grant Granted Mar 17, 2026
Patent 12571733
UNBIASED SORTING AND SEQUENCING OF OBJECTS VIA RANDOMIZED GATING SCHEMES
2y 5m to grant Granted Mar 10, 2026
Patent 12562239
Systems and Methods for Analyzing Mixed Cell Populations
2y 5m to grant Granted Feb 24, 2026
Patent 12460172
INFORMATION PROCESSING APPARATUS, CELL CULTURE SYSTEM, INFORMATION PROCESSING METHOD, AND INFORMATION PROCESSING PROGRAM
2y 5m to grant Granted Nov 04, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

5-6
Expected OA Rounds
59%
Grant Probability
93%
With Interview (+33.9%)
4y 1m
Median Time to Grant
High
PTA Risk
Based on 532 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in for Full Analysis

Enter your email to receive a magic link. No password needed.

Free tier: 3 strategy analyses per month